Patient
SITE004-0156
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE004 (DEU) (Dr. Tanaka)
consented 2026-03-03
Adverse events
5
Serious AEs
2
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 5
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-04 (study day 142); relationship: not assessed; serious criteria: hospitalization
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-01-25 (study day 132); relationship: NOT RELATED
Grade 3 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-01-22 (study day 129); relationship: not assessed; serious criteria: hospitalization
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-12-27 (study day 103); relationship: not assessed
Grade 1 Rash — outcome: RECOVERED/RESOLVED; onset 2022-10-11 (study day 26); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.